EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study

Jiafang Yao, Qiyin Sun, Dan Liu, Junling Lin, WenJuan Wang

BMC Cardiovascular Disorders · 16.05.2026 · 26 (1)

DOI: 10.1186/s12872-026-05931-5 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift BMC Cardiovascular Disorders, online erschienen am 16.05.2026. Verfasst von Jiafang Yao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Center, First affiliated Hospital of Huzhou University, No. 158 Plaza Back Road, Huzhou City, Zhejiang Province, 313000,…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Cholesterol, LDL, PCSK9 Inhibitors, Anticholesteremic Agents. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Funded by Huzhou Science and Technology Bureau, Public Welfare Applied Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCholesterol, LDLPCSK9 InhibitorsAnticholesteremic AgentsAntibodies, MonoclonalDyslipidemiasSerine Proteinase InhibitorsHumansFemaleTreatment OutcomeRetrospective StudiesMaleBiomarkersTime FactorsMiddle AgedApolipoprotein B-100Proprotein Convertase 9AgedAdult

Stichwörter der Autor:innen

AlirocumabApoBEvolocumabInclisiranLDL-CPCSK9 inhibitorReal-world study

Substanzen

Antibodies, Monoclonal, HumanizedalirocumabevolocumabCholesterol, LDLBiomarkersPCSK9 InhibitorsAnticholesteremic AgentsPCSK9 protein, humanAPOB protein, humanApolipoprotein B-100

Autor:innen und Institutionen

  • Department of Cardiovascular Center, First affiliated Hospital of Huzhou University, No. 158 Plaza Back Road, Huzhou City, Zhejiang Province, 313000, China.
  • Department of Nephrology, Huzhou Central, Hospital, Huzhou, China.
  • Department of Cardiovascular Center, First affiliated Hospital of Huzhou University, No. 158 Plaza Back Road, Huzhou City, Zhejiang Province, 313000, China. wwjyy0712@126.com.

Förderung

  • Funded by Huzhou Science and Technology Bureau, Public Welfare Applied Research Project

Zitieren

APA

Yao, J., Sun, Q., Liu, D., Lin, J., & Wang, W. (2026). Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study. BMC Cardiovascular Disorders, 26(1). https://doi.org/10.1186/s12872-026-05931-5

Vancouver

Yao J, Sun Q, Liu D, Lin J, Wang W. Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study. BMC Cardiovascular Disorders. 2026;26(1). doi:10.1186/s12872-026-05931-5

BibTeX
@article{Yao2026,
  author = {Yao, Jiafang and Sun, Qiyin and Liu, Dan and Lin, Junling and Wang, WenJuan},
  title = {Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study},
  journal = {BMC Cardiovascular Disorders},
  year = {2026},
  volume = {26},
  number = {1},
  doi = {10.1186/s12872-026-05931-5}
}
Kostenlos starten →